fbpx

Psychedelic Medicine

Association

Psychedelic Medicine

Association

Excerpts from the publication

Rationale
Posttraumatic stress disorder (PTSD) is a chronic and disabling disorder, for which available pharmacotherapies have limited efficacy. The authors’ previous proof-of-concept randomized controlled trial of single-dose intravenous ketamine infusion in individuals with PTSD showed significant and rapid PTSD symptom reduction 24 hours postinfusion. The present study is the first randomized controlled trial to test the efficacy and safety of repeated intravenous ketamine infusions for the treatment of chronic PTSD.

Methods
Individuals with chronic PTSD (N=30) were randomly assigned (1:1) to receive six infusions of ketamine (0.5 mg/kg) or midazolam (0.045 mg/kg) (psychoactive placebo control) over 2 consecutive weeks. Clinician-rated and self-report assessments were administered 24 hours after the first infusion and at weekly visits. The primary outcome measure was change in PTSD symptom severity, as assessed with the Clinician-Administered PTSD Scale for DSM-5 (CAPS-5), from baseline to 2 weeks (after completion of all infusions). Secondary outcome measures included the Impact of Event Scale–Revised, the Montgomery-Åsberg Depression Rating Scale (MADRS), and side effect measures.

Results
The ketamine group showed a significantly greater improvement in CAPS-5 and MADRS total scores than the midazolam group from baseline to week 2. At week 2, the mean CAPS-5 total score was 11.88 points (SE=3.96) lower in the ketamine group than in the midazolam group (d=1.13, 95% CI=0.36, 1.91). Sixty-seven percent of participants in the ketamine group were treatment responders, compared with 20% in the midazolam group. Among ketamine responders, the median time to loss of response was 27.5 days following the 2-week course of infusions. Ketamine infusions were well tolerated overall, without serious adverse events.

Conclusion
This randomized controlled trial provides the first evidence of efficacy of repeated ketamine infusions in reducing symptom severity in individuals with chronic PTSD. Further studies are warranted to understand ketamine’s full potential as a treatment for chronic PTSD.

Read more

A new approach methodology (NAM) for the prediction of (nor)ibogaine-induced cardiotoxicity in humans

Miaoying Shi, Sebastiaan Wesseling, Hans Bouwmeester and Ivonne M. C. M. Rietjens
July 2021

Antianhedonic Effect of Repeated Ketamine Infusions in Patients With Treatment Resistant Depression

Wilkowska A, Wiglusz MS, Gałuszko-Wegielnik M, Włodarczyk A, Cubała WJ.
October 2021

Safety of ibogaine administration in detoxification of opioid dependent individuals: a descriptive open-label observational study

T Knuijver, A Schellekens, M Belgers, R Donders, T van Oosteren, C Kramers , R J Verkes
February 2021

Ibogaine Detoxification Transitions Opioid and Cocaine Abusers Between Dependence and Abstinence: Clinical Observations and Treatment Outcomes

Deborah C. Mash, Linda Duque, Bryan Page, and Kathleen Allen-Ferdinand
June 2018